Replies to post #223806 on Biotech Values

[rfj1862]

I'm already into a well-granted startup that is developing a quick and accurate means to identify c. difficile strains in individual patients....

This could be interesting, although:
1. I am not sure what is so difficult or time consuming about the current modalities. Ribotyping and toxinotyping are fast enough. But more importantly:
2. I am not sure there would be any clinical utility associated with quick identification of strains, if the patient has CDAD they have CDAD regardless of the ribotype and it's treated in the same way. So what benefit is there, exactly, in identifying the strain rapidly, other than scientific interest? In other words, what clinically actionable information would this give you?